Regulatory Approval

Health Canada has greenlit drones for pesticide application, unlocking a new era of precision agriculture and positioning Canada in the global ag-tech race.

The FDA now allows ZYN to be marketed as lower-risk than cigarettes, a landmark win for harm reduction. But critics fear it opens a new door to nicotine addiction.

A key USCIS approval for a Detroit-area project reveals how the EB-5 investor visa program is channeling foreign funds into American job creation.

Once a quiet niche, the wAIHA market is now a battleground for J&J, Sanofi, and Novartis, with a 14.4% growth forecast and a new class of drugs.

Sarepta seeks full FDA approval for two Duchenne drugs, leaning on real-world evidence after a key trial missed its goal. A test case for rare disease innovation.

Thirty women have received a revolutionary absorbable scaffold that uses their own fat to regenerate breast tissue, promising an end to implant-related risks.

A legislative tour of Anfield Energy’s Velvet-Wood uranium mine highlights a controversial new playbook for boosting U.S. energy security through accelerated permitting.

Saluda Medical secures FDA approval for its CAP24™ paddle lead, expanding its advanced closed-loop neuromodulation to surgeons and chronic pain patients.

Webull Canada's new CIRO-approved crypto trading offers mainstream access, but a closer look reveals the unmitigated risks lurking beneath the regulatory sheen.

With stringent NYS approval secured, Fellow Health’s mail-in semen analysis enters a key market, signaling a major shift in at-home diagnostics and male reproductive care.

Luxembourg's STOKR gains rare CASP and PI licenses, setting a new standard for institutional tokenization as many rivals face EU market suspension.

New data on at-home lecanemab injections signals a major shift in Alzheimer's care, promising greater convenience and access for patients and caregivers.

With FDA Priority Review for its at-home therapy Enspryng, Roche is signaling a major disruption in the lucrative Thyroid Eye Disease market.

EdgeCortix's AI platform just got a major green light from the Pentagon's innovation arm. What does this mean for the future of battlefield tech and space AI?

Health Canada's approval of a generic Wegovy promises to slash costs and expand access, shifting the landscape for patients and the healthcare system.

With FDA clearance, Gain Therapeutics' GT-02287, an AI-discovered drug, advances to Phase 2, offering a new hope to modify Parkinson's, not just its symptoms.

With FDA approval for its pivotal TRIUMPH trial, Laplace Interventional is challenging giants in the lucrative tricuspid valve market. A strategic play.

Manitoba Hydro's plan for a major natural gas expansion sparks a fierce debate over energy needs, climate goals, and the future of the province's grid.

Onkos Surgical hit 500 cases with its NanoCept antibacterial coating. Is this nano-scale tech the key to winning the war on devastating surgical infections?